Sai Parenterals Ltd IPO

Diversified generic formulations player with an established track record.

Strategically located and accredited Manufacturing Facilities.

Strong focus on CDMO business.

Well-established sales network in India and overseas.

Track record of value-accretive acquisitions.

Experienced Promoters and Senior Management with extensive domain knowledge.

The companys Manufacturing Facilities are concentrated in Hyderabad, Telangana and Ongole, AndhraPradesh. The company is exposed to risks originating from slowdown or shutdown, economic, regulatory, political andother changes in this region, including natural disasters, which could adversely affect its business, results ofoperations and financial condition.

Out of its diversified product portfolio, approximately 44.78%, 47.64% and 92.03% during the Fiscals2025, 2024 and 2023, respectively of the companys Net Revenue from Operations was derived from the sale of injectables.Any reduction in demand for these products may adversely affect its business, financial condition, results ofoperations and cash flows.

The companys Manufacturing Facilities are subject to periodic inspections and audits by regulatory authoritiesand customers. The company may be subject to regulatory action which may damage its reputation, leading to an adverseeffect on the companys business, results of operations, financial condition and cash flows.

Majority of its key raw material purchases, being APIs, excipients and intermediates, are sourcedfrom a diversified supplier base, and the company does not enter into is not any long-term contractual agreements withthem. Any reduction of supplies or discontinuation of supplies from its top suppliers could have a materialadverse effect on the companys business, financial condition, results of operations and cash flows. Any fluctuation inprices of its raw materials may have a material adverse effect on the companys business, results of operations, prospectsand financial condition.

The companys success depends on its ability to successfully develop and commercialize new products in a timelymanner. Any failures to do so could adversely affect the companys business, results of operations and financial condition.

The companys business is dependent on the sale of products to a limited number of customers for a significantportion of its revenues. The loss of one or more such customers or the deterioration of their financial conditionor prospects could adversely affect its business, results of operations and financial condition.

The companys international business exposes us to complex management, legal, tax and economic risks, whichcould adversely affect its business, results of operations and financial condition.

There are outstanding legal proceedings involving the Company, Promoters, some of its Directorsand, the companys Material Subsidiary.

The company plans to expand and/or upgrade its Manufacturing Facilities from the Net Proceeds of the FreshIssue and will be required to briefly stop operations in Unit I and II till such plans are completed. The company hasestimated a period of 6 months for this disruption before both these units can resume operations. The company is alsodependent on third-party contractors and specialist agencies who will be executing the proposed expansionand/or upgradation plans.

The Indian pharmaceutical market is subject to extensive regulation and its failures to comply withthe existing and future regulatory requirements in the pharmaceutical market could adversely affect the companys business, results of operations and financial condition.